Pharmaceuticals, Biotechnology and Life Sciences
Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.
Teva Pharmaceutical Industries on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
U.S. Food and Drug Administration (FDA) has approved Teva’s Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD).
Teva Pharmaceutical Industries <TEVA.TA> may fire as many as 6,000 workers worldwide as part of a multi-year efficiency plan, Israel’s Calcalist news website reported on Thursday.
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
Another patent infringement against Teva has been filed in recent couple of months. Orexo AB has filed a patent infringement action in United States District Court for the District of Delaware against Actavis Elizabeth LLC, Actavis Pharma, Inc., and their parent company Teva.
Turbulent several months for Teva in which it saw many challenges and achievements saw the company loosing its CEO, several trials in the USA, one of which being for bribery, and patent related trials that Teva filed, and was filed against.
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
Teva ‘s chief executive officer Erez Vigodman has stepped down from its position, and the Israel’s largest drugmaker has appointed Dr. Yitzhak Peterburg, who has served as Chairman of the Teva’s Board since January 2015, as Interim President CEO.
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).